Aloxistatin (Standard)

Aloxistatin (Standard) is the analytical standard of Aloxistatin. This product is intended for research and analytical applications. Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.

Product Specifications

CAS Number

[88321-09-9]

Product Name Alternative

E64d (Standard) ; E64c ethyl ester (Standard)

UNSPSC

12352005

Target

Cathepsin; Reference Standards; SARS-CoV

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Field of Research

Neurological Disease

Smiles

O=C([C@H]1O[C@@H]1C(N[C@H](C(NCCC(C)C)=O)CC(C)C)=O)OCC

Molecular Formula

C17H30N2O5

Molecular Weight

342.43

References & Citations

[1]Doh-Ura K, et al. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74 (10) :4894-7.|[2]Konjar S, et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131 (2) :257-67.|[3]Mullins SR, et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393 (12) :1405-16.|[4]Hook G, et al. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J Alzheimers Dis. 2011;26 (2) :387-408.|[5]Cheng XW, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173 (2) :358-69.|[6]Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52 (5) :730-732.